Animal Drug Availability Act (ADAA) of 1996 - PowerPoint PPT Presentation

1 / 27
About This Presentation
Title:

Animal Drug Availability Act (ADAA) of 1996

Description:

Culmination of collaboration between FDA, a coalition of animal industry groups, ... Passed with strong bipartisan support. 3. ADAA: Impact on Animal Drug Review ... – PowerPoint PPT presentation

Number of Views:15
Avg rating:3.0/5.0
Slides: 28
Provided by: Ol9
Learn more at: http://www.fda.gov
Category:

less

Transcript and Presenter's Notes

Title: Animal Drug Availability Act (ADAA) of 1996


1
Animal Drug Availability Act (ADAA) of 1996
  • Legislative History of ADAA and Import Tolerances
  • Jarilyn Dupont
  • Senior Legislative Counsel
  • Food and Drug Administration
  • January 22, 2002

2
ADAA Public Law 104-250Signed into Law 10/09/96
  • ADAA was designed to increase the number of
    animal drugs on the market, without compromising
    FDAs mission to promote and protect the public
    health.
  • Culmination of collaboration between FDA, a
    coalition of animal industry groups, and
    manufacturers of animal drugs. Passed with strong
    bipartisan support.

3
ADAA Impact on Animal Drug Review
  • Section 2 Evidence of Effectiveness Injects
    flexibility in the review and approval process by
    amending the current definition of substantial
    evidence
  • Section 3 Limitation on Residues Supports
    flexible labeling to permit a range of
    acceptable or recommended doses to appear on the
    label

4
ADAA Impact on Animal Drug Review
  • Section 4 Import Tolerances
  • Permits the establishment of tolerance levels for
    drug residues in imported food products of animal
    origin
  • Section 5 Veterinary Feed Directive Creates a
    new category of drug approvals

5
ADAA Impact on Animal Drug Review
  • Section 6 Feed Mill Licenses
  • Establishes a new system for licensing feed mills

6
ADAA Path to Passage
  • Senate
  • 05/09/95 S. 773 Introduced
  • 12/13/95 S.1477 Introduced
  • 02/21/96 Hearings on S. 1477
  • 03/28/96 S. 1477 Passed Committee
  • 06/20/96 S. 1477 Reported to Senate
  • 09/24/96 Committee Mark-up of S. 773 - Passes
    Senate (identical to H.R. 2508)
  • 9/28/96 Presented to
  • President
  • 10/09/96 Signed into Law
  • House
  • 10/19/95 H.R. 2508 Introduced
  • 03/29/96 H.R. 3200 Introduced
  • 05/01/96 Hearings on H.R. 3200
  • 09/19/96 Committee Mark-up of H.R. 3200
  • 09/24/96 H.R. 2508 Passes House (identical to
    S.773)
  • 09/28/96 Presented to President
  • 10/09/96 Signed into Law

7
ADAA Chronology
  • S. 773, ADAA, introduced 05/09/95 by
  • Senator Nancy Kassebaum 19 cosponsors -
    referred to Senate Labor Committee
  • H.R. 2508, ADAA, introduced 10/19/95 by Rep.
    Wayne Allard 71 cosponsors - referred to House
    Commerce Committee

8
ADAA Chronology
  • S. 773 and H.R. 2508, nearly identical. Neither
    contained an import tolerance provision
  • In floor remarks, sponsors stated the reason for
    the bill was concern that the animal drug
    approval process had become cumbersome and
    unpredictable and increasingly prolonged and
    complicated.

9
ADAA Chronology
  • No further official action on S. 773 or H.R. 2508
    until 1996
  • 12/13/95 S. 1477, The FDA Performance and
    Accountability Act introduced by Senator Nancy
    Kassebaum 4 cosponsors
  • Comprehensive Reform bill, contained animal drug
    reform provisions

10
ADAA Chronology
  • 01/1996 Reinventing Food Regulations, National
    Performance Review - Includes proposal to
    enable FDA to focus its reviews on the safety
    of the drug residue in the imported food
    product, among other animal drug initiatives

11
ADAA Chronology
  • 02/21/96 Senate Labor Committee hearings on S.
    1477 - Dr. Kessler testified
  • 03/28/96 S. 1477 Passed Committee
  • 03/29/96 H.R. 3200, Food Amendments and the
    Animal Drug Availability Act of 1996 introduced
    by Rep. Scott Klug.

12
ADAA Chronology
  • H.R. 3200 was 1 of 3 FDA Reform bills.
  • Title II of H.R. 3200 - ADAA (Evidence of
    Effectiveness and Limitation on Residues verbatim
    from H.R. 2508 - also picks up provisions from
    the REGO initiative)

13
ADAA Chronology
  • 05/01-02/96 House Commerce Subcommittee Hearings
    on the 3 FDA Reform Bills - Dr. Kessler testified
  • 05/1996 Reinventing the Regulation of Animal
    Drugs National Performance Review

14
ADAA Chronology
  • 05/29/96 One Hour Special Order in House on 3
    FDA Reform bills
  • 06/20/96 S. 1477 Reported to Senate
  • Between 06/96 - 09/96 - Committees, FDA and
    Industry Coalition working on bills

15
ADAA Chronology
  • 09/19/96 Committee Mark-Up of H.R. 2508
    Discharged, included Section 4, Import Tolerance
  • 09/24/96 H.R. 2508 Reported and Passed the House
    by Voice Vote - (now identical to S.773)

16
ADAA Chronology
  • 09/24/96 Committee Mark-Up of S. 773 Discharged,
    included Section 4, Import Tolerance
  • 09/24/96 S. 773 Passed Senate by Unanimous
    Consent (now identical to H.R. 2508)

17
ADAA Chronology
  • 09/28/96 Presented to the President
  • 10/09/96 Signed Became Public Law

18
Section 4. Import Tolerance
  • Section 4. Import Tolerances.
  • Section 512(a) (21 U.S.C. 360b(a)) is amended
    by adding the following new paragraph at the end
  • '(6) For purposes of section 402(a)(2)(D), a
    use or intended use of a new animal drug shall
    not be deemed unsafe under this section if the
    Secretary establishes a tolerance for such drug
    and any edible portion of any animal imported
    into the United States does not contain residues
    exceeding such tolerance. In establishing such
    tolerance, the Secretary shall rely on data
    sufficient to demonstrate that a proposed
    tolerance is safe based on similar food safety
    criteria used by the Secretary to establish
    tolerances for applications for new animal drugs
    filed under subsection (b)(1). The Secretary may
    consider and rely on data submitted by the drug
    manufacturer, including data submitted to
    appropriate regulatory authorities in any country
    where the new animal drug is lawfully used or
    data available from a relevant international
    organization, to the extent such data are not
    inconsistent with the criteria used by the
    Secretary to establish a tolerance for
    applications for new animal drugs filed under
    subsection (b)(1). For purposes of this
    paragraph, 'relevant international organization'
    means the Codex Alimenterius Commission or other
    international organization deemed appropriate by
    the Secretary. The Secretary may, under
    procedures specified by regulation, revoke a
    tolerance established under this new paragraph if
    information demonstrates that the use of the new
    animal drug under actual use conditions results
    in food being imported into the United States
    with residues exceeding the tolerance or if
    scientific evidence shows the tolerance to be
    unsafe.'

19
Import TolerancesCongressional Intent
  • 3 Members and 1 Senator mentioned import
    tolerances in floor remarks during passage
  • 09/24/96 House and Senate Floor
  • Finally, the bill authorizes FDA to establish
    import tolerances for new animal drugs not
    approved in the U.S. (Mr. Bilirakis)

20
Import TolerancesCongressional Intent
  • We are pleased that this legislation
    incorporates FDA proposals included in the Vice
    President's reinventing Government
    initiatives,..., and another that will authorize
    FDA to establish import tolerances for animal
    drugs not approved for use in the United States.
  • (Mr. Manton)

21
Import TolerancesCongressional Intent
  • "In addition, the bill implements two items from
    the National Performance Review. It would allow
    FDA to set tolerances for drugs used on farm
    animals whose meat ultimately is imported into
    the United States. (Mr. Deutsch)

22
Import TolerancesCongressional Intent
  • the billpermits FDA to set import tolerances
    for drugs used in other countries (Senator
    Lugar)

23
Import TolerancesCongressional Intent
  • 09/24/96 House Commerce Committee issued its
    report on ADAA (Report 104-823)
  • It contained two references to import tolerances

24
Import TolerancesCongressional Intent
  • A letter from June E. O'Neill, Director of the
    Congressional Budget Office to Chairman Tom
    Bliley. Comments regarding import tolerances
    include
  • "...The bill would direct the Secretary of Health
    and Human Services to establish tolerance levels
    for residues of veterinary drugs in imported
    animal products intended for human consumption.
    ... Tolerance Standards. Section 4 of the bill
    would require that the residues from animal drugs
    in edible animals imported into the United States
    meet tolerance standards to be set by the
    Secretary. These animal products could not be
    deemed unsafe unless their residue levels
    exceeded the specified tolerance levels. Under
    current law, the United States Department of
    Agriculture monitors residues in imported animal
    food products, sometimes in consultation with the
    Food and Drug Administration (FDA). However,
    this section would place a new formal requirement
    on the importation of edible animals. Based on
    information from FDA staff, CBO expects that the
    tolerance standards set by the Secretary would
    not differ significantly from current practice.
    Thus, this provision would not have significant
    costs for the federal government or the private
    sector." (Page 11)

25
Import TolerancesCongressional Intent
  • Section-by-section analysis of the legislation
  • Section 4 amends section 512(a) to permit FDA to
    establish a tolerance for residues of an animal
    drug in human foods, when the drug is not
    approved for use in the United States but
    imported food products of animal origin may
    contain residues of that drug. There are
    appropriate instances in which food producing
    animals raised in other countries are treated
    with animal drugs that are not approved in the
    United States. For example, the disease or
    condition treated by the drug does not occur in
    the United States. There have been concerns
    about residues of such drugs in food products
    derived from these animals, imported into the
    United States.

26
Import TolerancesCongressional Intent
  • Section-by-Section (continued)
  • This provision authorizes FDA to establish a
    safe tolerance using criteria similar to those
    that it would apply in reviewing the human food
    safety aspects of an animal drug for which
    approval is sought in the United States. FDA may
    rely on data generated by the drug manufacturer
    or on data from a relevant international
    organization such as the Codex Alimentarius
    Commission. This is a step in the right
    direction of international harmonization of
    regulatory requirements.
  • If an international standard on which FDA relied
    changes or new information (from either
    experience or scientific data) shows the
    tolerance is no longer safe, FDA may change or
    revoke the tolerance. In addition, section 4
    provides that the tolerance may be revoked if
    information shows use of the animal drug under
    actual use conditions results in food being
    imported into the United States with residues
    exceeding the tolerance (Page 16 17)

27
ANPR Import Tolerances
  • 08/10/01 FDA published an Advance Notice of
    Proposed Rulemaking to solicit comments on
    establishing drug residue tolerances (import
    tolerances) for imported food products of animal
    origin for drugs approved in other countries, but
    not approved in the U.S.
Write a Comment
User Comments (0)
About PowerShow.com